{"filing":{"accession_number":"0001493152-26-034079","cik":"0001430306","ticker":"TNXP","company_name":"Tonix Pharmaceuticals Holding Corp.","form":"8-K","filing_date":"2026-07-21","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1430306/000149315226034079/form8-k.htm"},"events":[{"id":19097,"run_id":17185,"accession_number":"0001493152-26-034079","anchor_item_number":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Dr. Gregory M. Sullivan, Chief Medical Officer, informed the Company on July 20, 2026 that he will retire from his role effective August 20, 2026. This is a clear executive departure disclosed under Item 5.02, representing the departure of a named officer from the Company.","company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","filing_date":"2026-07-21","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":18093,"accession_number":"0001493152-26-034079","item_number":null,"item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Dr. Gregory M. Sullivan, Chief Medical Officer, informed the Company on July 20, 2026 that he will retire from his role effective August 20, 2026. This is a clear executive departure disclosed under Item 5.02, representing the departure of a named officer from the Company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-21T20:07:03.970643+00:00","company_name":"Tonix Pharmaceuticals Holding Corp.","ticker":"TNXP","filing_date":"2026-07-21"}]}